Officials said that the US states and territories are ready to start distributing the vaccine within 24 hours of obtaining the necessary regulatory approval.
Officials said complex storage requirements would not be a barrier to getting the vaccine for all Americans.
Pfizer and Biontech, the drug maker, said Wednesday that they may obtain approval from US and European regulatory agencies for the emergency use of their Covid-19 vaccine next month, after the results of the final trials showed that the vaccine’s success rate is 95% and there are no serious side effects.
And it turns out that the effectiveness of the vaccine is stable in different age groups and ethnicities, which is a promising sign.
The success rate of the vaccine, which the American Pfizer and its German partner, BioNTech, worked on, is the highest of any vaccine tested in the last clinical stages so far, and experts say it is a great achievement in the race to end the pandemic.
Biontech CEO Ugur Shaheen told Reuters TV that the US Food and Drug Administration may grant approval for the emergency use of the vaccine before the end of the first half of December or the beginning of the second half of the month.
He added that it is possible to obtain conditional approval from the European Union in the second half of next December.
Pfizer said that 170 volunteers in the trial, which included more than 43,000, were infected with Covid-19, but 162 of them received a placebo vaccine, which means that the effectiveness of the vaccine is 95%. Among those who had a severe infection from Covid-19, one received the vaccine.
A source familiar with the matter said that the Advisory Committee on Vaccines of the US Food and Drug Administration plans to meet in principle from 8 to 10 December next, but these dates are subject to change.
Pfizer said it expects to produce as much as 50 million doses this year, sufficient to protect 25 million people, and then produce up to 1.3 billion doses in 2021.
Russian real estate
And Russian President Vladimir Putin said Tuesday that India and China may start production of the Russian vaccine, “Sputnik V”, calling on the BRICS countries for developing countries to produce the two vaccines that Moscow said it had developed.
The results of the preliminary experiments showed, Wednesday, that the experimental Sinovac Biotech vaccine to prevent Covid-19 stimulated a rapid immune response, but the level of antibodies that it produced was below the level of those recovering from the disease.
The new Corona virus continues to spread rapidly in various parts of the world, and at the same time governments have entered a feverish race to obtain the vaccines that are expected to be adopted in the next few weeks.
According to figures published by Reuters on Wednesday, the emerging corona virus has infected 55 million around the world, of whom more than 1.3 million have died.
The United States is still the country most affected by the Coronavirus in terms of infections and deaths, as it has recorded 11.3 million infections, and about a quarter of a million deaths.
In second place comes India with 8.9 million injuries and about 131 thousand deaths, then Brazil with 5.9 million injuries and more than 166 thousand deaths.
France ranks fourth with more than 2 million injuries, 46 thousand, and 273 thousand deaths, followed by Russia with two million injuries and 44 thousand deaths.
The virus is spreading spectacularly in Europe, and data from the Robert Koch Institute for Infectious Diseases on Wednesday showed that 175,61 new infections were recorded in Germany, bringing the total to more than 833,000 infections.
The data revealed 305 new deaths, which brings the total number to 131 thousand and 19 cases.